Literature DB >> 23319554

Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of pneumocystis pneumonia.

Michael J Linke1, Alan Ashbaugh, Margaret S Collins, Keeley Lynch, Melanie T Cushion.   

Abstract

Pneumocystis spp. are yeast-like fungi that cause pneumocystis pneumonia (PcP) in immunocompromised individuals and exacerbate chronic lung diseases in immunocompetent individuals. The Pneumocystis life cycle includes trophic forms and asci (cyst forms). The cell walls of Pneumocystis asci contain β-1,3-D-glucan, and treatment of PcP with β-1,3-D-glucan synthase inhibitors, such as anidulafungin, results in depletion of asci, but not trophic forms. The pulmonary host response during immune reconstitution (IR)-mediated clearance of PcP in anidulafungin-treated and untreated mice was characterized to identify ascus-specific responses. During IR, similar numbers of trophic forms were present in the anidulafungin-treated and untreated mice; however, asci were only present in the untreated mice. IR resulted in a significant reduction of trophic forms from the lungs in both groups and asci in the untreated group. The presence of asci in untreated mice correlated with increased β-glucan content in the lungs. The untreated mice mounted immune responses associated with a deleterious host inflammatory response, including increased CD8(+) T cell influx and expression of macrophage inflammatory response markers. A more robust cellular response was also observed in the untreated mice, with increased numbers of macrophages and neutrophils that were associated with greater lung damage. Markers of a Th17 response were also elevated in the untreated mice. These results suggest that the host mounts unique responses to asci and trophic forms. That these 2 life cycle stages provoked distinct host response profiles has significant implications for clearance and interpretation of the host immune responses to PcP.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23319554      PMCID: PMC3584873          DOI: 10.1128/IAI.01181-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  Sensitized CD8+ T cells fail to control organism burden but accelerate the onset of lung injury during Pneumocystis carinii pneumonia.

Authors:  Francis Gigliotti; Elliott L Crow; Samir P Bhagwat; Terry W Wright
Journal:  Infect Immun       Date:  2006-08-28       Impact factor: 3.441

2.  Efficient resolution of Pneumocystis murina infection in surfactant protein A-deficient mice following withdrawal of corticosteroid-induced immunosuppression.

Authors:  Michael Linke; Alan Ashbaugh; Judith Koch; Reiko Tanaka; Peter Walzer
Journal:  J Med Microbiol       Date:  2006-02       Impact factor: 2.472

Review 3.  Immune reconstitution syndrome associated with opportunistic mycoses.

Authors:  Nina Singh; John R Perfect
Journal:  Lancet Infect Dis       Date:  2007-06       Impact factor: 25.071

4.  Use of a serum (1-->3)-beta-D-glucan assay for diagnosis and follow-up of Pneumocystis jiroveci pneumonia.

Authors:  María Soledad Cuétara; Almudena Alhambra; Fernando Chaves; María Dolores Moragues; José Pontón; Amalia del Palacio
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079

5.  Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia.

Authors:  Laura McKinley; Alison J Logar; Florencia McAllister; Mingquan Zheng; Chad Steele; Jay K Kolls
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

6.  Biofilm formation by Pneumocystis spp.

Authors:  Melanie T Cushion; Margaret S Collins; Michael J Linke
Journal:  Eukaryot Cell       Date:  2008-09-26

7.  Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure.

Authors:  T M Hohl; M Feldmesser; D S Perlin; E G Pamer
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

8.  Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae.

Authors:  Gregory A Lamaris; Russell E Lewis; Georgios Chamilos; Gregory S May; Amar Safdar; Thomas J Walsh; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

9.  Serum indicators for the diagnosis of pneumocystis pneumonia.

Authors:  Sadatomo Tasaka; Naoki Hasegawa; Seiki Kobayashi; Wakako Yamada; Tomoyasu Nishimura; Tsutomu Takeuchi; Akitoshi Ishizaka
Journal:  Chest       Date:  2007-04       Impact factor: 9.410

10.  Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials.

Authors:  Matthias Briel; Remy Boscacci; Hansjakob Furrer; Heiner C Bucher
Journal:  BMC Infect Dis       Date:  2005-11-07       Impact factor: 3.090

View more
  18 in total

Review 1.  Pneumocystis.

Authors:  Francis Gigliotti; Andrew H Limper; Terry Wright
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 2.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

3.  The Trophic Life Cycle Stage of the Opportunistic Fungal Pathogen Pneumocystis murina Hinders the Ability of Dendritic Cells To Stimulate CD4+ T Cell Responses.

Authors:  Heather M Evans; Andrew Simpson; Shu Shen; Arnold J Stromberg; Carol L Pickett; Beth A Garvy
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

4.  β-Glucans Are Masked but Contribute to Pulmonary Inflammation During Pneumocystis Pneumonia.

Authors:  Geetha Kutty; A Sally Davis; Gabriela A Ferreyra; Ju Qiu; Da Wei Huang; Monica Sassi; Lisa Bishop; Grace Handley; Brad Sherman; Richard Lempicki; Joseph A Kovacs
Journal:  J Infect Dis       Date:  2016-06-19       Impact factor: 5.226

5.  Dectin immunoadhesins and pneumocystis pneumonia.

Authors:  David M Ricks; Kong Chen; Mingquan Zheng; Chad Steele; Jay K Kolls
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

Review 6.  Pathological and protective immunity to Pneumocystis infection.

Authors:  Taylor Eddens; Jay K Kolls
Journal:  Semin Immunopathol       Date:  2014-11-25       Impact factor: 9.623

7.  Efficacy of caspofungin combined with trimethoprim/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia.

Authors:  Gensheng Zhang; Miaomiao Chen; Shufang Zhang; Hongwei Zhou; Xiaozhen Ji; Jiachang Cai; Tianzheng Lou; Wei Cui; Ning Zhang
Journal:  Exp Ther Med       Date:  2017-11-16       Impact factor: 2.447

8.  The life cycle stages of Pneumocystis murina have opposing effects on the immune response to this opportunistic, fungal pathogen.

Authors:  Heather M Evans; Grady L Bryant; Beth A Garvy
Journal:  Infect Immun       Date:  2016-08-29       Impact factor: 3.441

9.  Targeting CARD9 with Small-Molecule Therapeutics Inhibits Innate Immune Signaling and Inflammatory Response to Pneumocystis carinii β-Glucans.

Authors:  Theodore J Kottom; Eva M Carmona; Andrew H Limper
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

10.  The trophic life cycle stage of Pneumocystis species induces protective adaptive responses without inflammation-mediated progression to pneumonia.

Authors:  Heather M Evans; Beth A Garvy
Journal:  Med Mycol       Date:  2018-11-01       Impact factor: 4.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.